STUDY OF POTENTIAL LABORATORY MARKERS OF SYSTEMIC LUPUS ERYTHOMUS AND THEIR RELATIONSHIP WITH CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS
Summary. Introduction. The search for biomarkers of systemic lupus erythematosus (SLE), which would allow to increase the effectiveness of diagnosis, monitoring, risk stratification and prediction of individual response to treatment, remains an urgent issue that is currently being actively studied. The aim of the work is to supplement the existing data on interleukin-2 (IL-2), serum amyloid A (SAA), ferritin, vascular endothelial growth factor A (vascular endothelial growth factor A — VEGF-A), soluble receptor of vascular endothelial growth factor type 1 (sVEGF-R1) and endothelin-1 (ET-1) in SLE, to study their relationships with routine laboratory parameters and clinical manifestations of the disease. Materials and methods. The study included 38 SLE patients, who underwent inpatient treatment at the SI «NSC» Institute of Cardiology, Clinical and Regenerative Medicine named after Acad. M.D. Strazhesko NAMS of Ukraine» in 2021–2023 and 14 healthy persons, comparable in age and sex ratio. Results. Serum levels of SAA, ferritin VEGF-A, sVEGF-R1 and ET-1 are significantly higher in patients with SLE compared to the control group. ET-1 and SAA are markers of high disease activity in SLE. According to the concentration of IL-2 in blood serum, groups with low and high levels can be distinguished; the latter have a lower level of VEGF-A and a higher level of C-reactive protein. Conclusions. The obtained results are of the theoretical importance and require further research on larger groups of patients.
Leave a comment